Nebido in the treatment of hypogonadism syndrome and its complications in men


Cite item

Full Text

Abstract

The article presents original experience with use of undecanoate (nebido, BayerHealthcare Pharmaceuticals, Germany) in androgenic testosteron replacement therapy in males with hypogonadism. Prospective studies of nebido efficacy were made in males with vein-occlusive erectile dysfunction (n = 20), chronic pelvic pain syndrome (n = 77), metabolic syndrome (n = 170). Retrospective studies assessed efficacy of nebido monotherapy in patients with erectile dysfunction and hypogonadism (n = 34), hematological and urological safety of the drug (n = 40). Laboratory monitoring was performed in all the studies according to ISSAM recommendations. The patients were not included in contraindications to androgenic therapy. Nebido treatment significantly improved libido and erectile function, efficacy of phosphodiesterase of type 5 inhibiors used in moderate and severe erectile dysfunction. Depressive, asthenic, pain symptoms declined in males with chronic pelvic pain. Body fat reduced in metabolic syndrome with alleviation of its other components. Insignificant rise of hemoglobin level and packed cell volume was observed in some patients while a PSA level increase was clinically significant in 10% patients who had initial PSA > 2.5 ng/ml and acromegalia. Also, nebido depressed production of gonadotropins and spermatogenesis. Thus, nebido is highly effective in sexual dysfunction and other somatic disorders caused by hypogonadism. Nebido does not induce severe side effects, but clinically significant rise of PSA level requires treatment discontinuation and more careful urological examination. In view of nebido ability to suppress spermatogenesis, the drug should not be used in reproductively active men.

References

  1. Finley M. R., Curruthers M. E. Androgens, the prostate and safety of testosterone treatment. Aging Male 2006; 9 (1): 4.
  2. Курбатов Д. Г., Кузнецкий Ю. Я., Роживанов Р. В., Дубский С. А. Применение тестостерона в комбинированном лечении больных синдромом хронической тазовой боли и андрогенным дефицитом. Вестн. репрод. здоровья 2008; 3- 4: 39-44.
  3. Shabsigh R. The effects of testosterone on the cavernous tissue and erectile function. Wld J. Urol. 1997; 15 (1): 21-26.
  4. Vinik A., Richardson D. Erectile dysfunction in diabetes. Diabet. Rev. 1998; 6 (1): 16-33.
  5. Yassin A., Saad F. Dramatic improvement of penile venous leakage upon testosterone administration. A case report and review of literature. Authors J. Compilat. 2006; 38: 34-37.
  6. Rochira V., Balestrieri A., Madeo B. et al. Sildenafil improves sleep-related erections in hypogonadal men: Evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. J. Androl. 2006; 27: 165-175.
  7. Stellate R. K., Feldman H. A., Hamdy O. et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabet. Care. 2000; 23 (4): 490-494.
  8. Роживанов Р. В., Курбатов Д. Г. Особенности терапии эректильной дисфункции у пациентов с гипогонадизмом. Врач 2009; 3: 65-69.
  9. Курбатов Д. Г., Щетинин В. В., Китаев С. В. Роль магнитно-резонансной томографии в диагностике и лечении васкулогенной эректильной дисфункции. Мед. визуализ. 2005; 4: 120-127.
  10. Тишова Ю. А., Калинченко С. Ю. Роль коррекции гипогонадизма в лечении метаболического синдрома у мужчин и аспекты безопасности терапии препаратом тестостерона пролонгированного действия (результаты двойного слепого рандомизированного плацебо-контролируемого исследования). Ожирение и метаболизм 2010; 2: 36-43.
  11. Роживанов Р. В., Курбатов Д. Г. Гематологические и урологические аспекты безопасности заместительной андрогенной терапии препаратом тестостерона ундеканоата пролонгированного действия у пациентов с гипогонадизмом. Пробл. эндокринол. 2009; 55 (6): 31-35.
  12. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment 9 and monitoring of late-onset hypogonadism in males. Aging Male 2008; 1-8.
  13. Litwin M., Mcnaughton Collins M., Fowler Jr. F. et al. The National Institutes of Health chronic prostatitis symptom index (NIH-CPSI): Development and validation of a new outcome measure. J. Urol. (Baltimore) 1999; 162: 369-375.
  14. Yassin A., Saad F. Long-acting testosterone ester injection as a first line therapy in hypogonadal patients with erectile dysfunction. Int. J. Androl. 2005; 28 (Suppl. 1): 53.
  15. Курбатов Д. Г., Traish А., Дубский С. А. и др. Коррекция веноокклюзивной эректильной дисфункции у пациентов с гипогонадизмом. Вестн. репрод. здоровья 2009; 1: 32-37.
  16. Shen Z. J., Zhou X. L., Lu Y. L., Chen Z. D. Effect of androgen deprivation on penile ultrastructure. Asian J. Androl. 2003; 5: 33-36.
  17. Traish A. M., Toselli P., Jeong S. J. Adipocyte accumulation in penile corpus cav.-ernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency. J. Androl. 2005; 26: 242-248.
  18. Aversa A., Isidori A. M., Spera G. et al. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin. Endocrinol. 2003; 58: 632-638.
  19. Foresta C., Caretta N., Rossato M. et al. Role of androgens in erectile function. J. Urol. (Baltimore) 2004; 171: 2358-2362.
  20. Воробьева О. В., Акарачкова Е. С. Роль депрессии в хронизации дорсалгии: подходы к терапевтической коррекции. Журн. неврол. и психиатр. 2004; 8: 46-50.
  21. Pope H. S. G., Cohane G. H., Kanayama G. et al. Testosterone gel supplementation for men with refractory depression: a randomized, placebocontrolled trial. Am. J. Psychiatry 2003; 160: 105-111.
  22. Alexander G. M., Swerdloff R. S., Wang C. et al. Androgen-behavior correlations in hypogonadal men and eugonadal men. I. Mood and response to auditory stimuli. Horm. Behav. 1997; 31: 110-119.
  23. Anderson R. A., Bancroft J., Wu F. C. W. The effects of exogenous testosterone on sexuality and mood of normal men. J. Clin. Endocrinol. Metab. 1992; 75: 1503-1507.
  24. Gu Y. Q., Wang X. H., Xu D. et al. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J. Endocrinol. 2003; 88 (2): 562-568.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies